• Explore /
  • Poster
  • / ZENYTH-ESO: Master protocol to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and myxoid/round cell liposarcoma [Substudy 3, GSK4427296].

ZENYTH-ESO: Master protocol to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and myxoid/round cell liposarcoma [Substudy 3, GSK4427296].

Abstract Poster

Authors

Dejka Araujo

Dejka M. Araujo

University of Texas MD Anderson Cancer Center, Department of Sarcoma Medical Oncology, Houston, TX

Dejka M. Araujo , Brian H. Ladle , Kai He , Benjamin Powers , Amanda McGillivray , Ionel Mitrica , Wenlei Liu , Nitin Patel , Sandra P. D'Angelo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Cellular Immmunotherapy

Clinical Trial Registration Number

NCT04526509

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS2681)

DOI

10.1200/JCO.2022.40.16_suppl.TPS2681

Abstract #

TPS2681

Poster Bd #

329b

Abstract Disclosures

Similar Posters

First Author: Sandra P. D'Angelo

First Author: Adam Jacob Schoenfeld

First Author: Aaron Rapoport

Poster

2024 ASCO Annual Meeting

<span>Phase IIA study of high-affinity TCR-T (TAEST16001) targeting NY-ESO-1 in soft tissue sarcoma.</span>

Phase IIA study of high-affinity TCR-T (TAEST16001) targeting NY-ESO-1 in soft tissue sarcoma.

First Author: Jiayong Liu